Brian Mueller Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Brian Mueller.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Brian Mueller. Brian Mueller is EVP, Chief Financial Officer in BIOMARIN PHARMACEUTICAL INC ($BMRN) and SVP, Acting CFO in BIOMARIN PHARMACEUTICAL INC ($BMRN) and SVP, Corporate Controller in BIOMARIN PHARMACEUTICAL INC ($BMRN) and SVP, Finance and CAO in BIOMARIN PHARMACEUTICAL INC ($BMRN) and VP, Corporate Controller in BIOMARIN PHARMACEUTICAL INC ($BMRN) and in Anthera Pharmaceuticals Inc ($ANTH).
Latest Insider Trading Transactions of Brian Mueller
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 11 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Option Exercise | M | 28.23 | 6,709 | 189,395 | 0 | |
May 11 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Sell | S | 79.50 | 6,709 | 533,366 | 31,357 | 38.1 K to 31.4 K (-17.62 %) |
May 11 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Buy | M | 28.23 | 6,709 | 189,395 | 38,066 | 31.4 K to 38.1 K (+21.40 %) |
May 11 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Grant | A | 62.41 | 341 | 21,281 | 31,357 | 31 K to 31.4 K (+1.10 %) |
Apr 02 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Sell | S | 76.30 | 5,692 | 434,300 | 31,016 | 36.7 K to 31 K (-15.51 %) |
Mar 23 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Payment of Exercise | F | 78.52 | 516 | 40,516 | 36,708 | 37.2 K to 36.7 K (-1.39 %) |
Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Option Exercise | A | 78.39 | 24,890 | 1,951,127 | 24,890 | |
Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Payment of Exercise | F | 77.21 | 582 | 44,936 | 37,224 | 37.8 K to 37.2 K (-1.54 %) |
Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Payment of Exercise | F | 78.39 | 994 | 77,920 | 37,806 | 38.8 K to 37.8 K (-2.56 %) |
Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Grant | A | 0.00 | 10,110 | 0 | 38,800 | 28.7 K to 38.8 K (+35.24 %) |
Feb 04 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Payment of Exercise | F | 82.82 | 1,071 | 88,700 | 28,673 | 29.7 K to 28.7 K (-3.60 %) |
Jun 30 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Option Exercise | A | 122.18 | 13,230 | 1,616,441 | 13,230 | |
Jun 30 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Grant | A | 0.00 | 4,640 | 0 | 29,744 | 25.1 K to 29.7 K (+18.48 %) |
Jun 30 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Grant | A | 62.59 | 323 | 20,215 | 25,104 | 24.8 K to 25.1 K (+1.30 %) |
Jun 30 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Option Exercise | A | 122.18 | 13,230 | 1,616,441 | 13,230 | |
Jun 30 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Grant | A | 0.00 | 4,640 | 0 | 29,744 | 25.1 K to 29.7 K (+18.48 %) |
Jun 30 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Grant | A | 62.59 | 323 | 20,215 | 25,104 | 24.8 K to 25.1 K (+1.30 %) |
Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Payment of Exercise | F | 73.05 | 414 | 30,243 | 24,781 | 25.2 K to 24.8 K (-1.64 %) |
Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Option Exercise | A | 73.82 | 9,600 | 708,672 | 9,600 | |
Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Grant | A | 0.00 | 6,730 | 0 | 25,195 | 18.5 K to 25.2 K (+36.45 %) |
Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Payment of Exercise | F | 84.50 | 1,303 | 110,104 | 18,465 | 19.8 K to 18.5 K (-6.59 %) |
Feb 04 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Grant | A | 0.00 | 5,800 | 0 | 19,768 | 14 K to 19.8 K (+41.52 %) |
Feb 04 2020 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Acting CFO | Grant | A | 62.23 | 9 | 560 | 13,968 | 14 K to 14 K (+0.06 %) |
Jun 07 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Finance and CA ... | Grant | A | 68.78 | 299 | 20,566 | 13,959 | 13.7 K to 14 K (+2.19 %) |
Apr 09 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 94.00 | 2,953 | 277,582 | 13,660 | 16.6 K to 13.7 K (-17.78 %) |
Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 88.05 | 415 | 36,541 | 16,613 | 17 K to 16.6 K (-2.44 %) |
Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | A | 94.53 | 9,650 | 912,215 | 9,650 | |
Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 0.00 | 5,780 | 0 | 17,028 | 11.2 K to 17 K (+51.39 %) |
Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 94.53 | 1,149 | 108,615 | 11,248 | 12.4 K to 11.2 K (-9.27 %) |
Dec 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 68.78 | 22 | 1,513 | 12,397 | 12.4 K to 12.4 K (+0.18 %) |
Jun 26 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | M | 28.23 | 2,491 | 70,321 | 1,718 | |
Jun 26 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | M | 28.23 | 2,491 | 70,321 | 1,718 | |
Jun 26 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 99.50 | 2,491 | 247,855 | 12,375 | 14.9 K to 12.4 K (-16.76 %) |
Jun 26 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 99.50 | 2,491 | 247,855 | 12,375 | 14.9 K to 12.4 K (-16.76 %) |
Jun 26 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Buy | M | 28.23 | 2,491 | 70,321 | 14,866 | 12.4 K to 14.9 K (+20.13 %) |
Jun 26 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Buy | M | 28.23 | 2,491 | 70,321 | 14,866 | 12.4 K to 14.9 K (+20.13 %) |
Jun 26 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 99.50 | 654 | 65,073 | 12,375 | 13 K to 12.4 K (-5.02 %) |
Jun 26 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 99.50 | 654 | 65,073 | 12,375 | 13 K to 12.4 K (-5.02 %) |
Jun 18 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 94.50 | 2,021 | 190,985 | 13,029 | 15.1 K to 13 K (-13.43 %) |
Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 92.07 | 346 | 31,856 | 15,050 | 15.4 K to 15.1 K (-2.25 %) |
May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 89.50 | 2,450 | 219,275 | 15,396 | 17.8 K to 15.4 K (-13.73 %) |
May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 68.78 | 287 | 19,740 | 17,846 | 17.6 K to 17.8 K (+1.63 %) |
Mar 26 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 81.36 | 414 | 33,683 | 17,559 | 18 K to 17.6 K (-2.30 %) |
Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | A | 83.57 | 9,120 | 762,158 | 9,120 | |
Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 0.00 | 5,710 | 0 | 17,973 | 12.3 K to 18 K (+46.56 %) |
Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 84.10 | 346 | 29,099 | 12,263 | 12.6 K to 12.3 K (-2.74 %) |
Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 83.57 | 309 | 25,823 | 12,609 | 12.9 K to 12.6 K (-2.39 %) |
Jan 09 2018 | ANTH | Anthera Pharmaceut ... | Mueller Brian | Option Exercise | A | 1.65 | 84,705 | 139,763 | 84,705 | ||
Jan 09 2018 | ANTH | Anthera Pharmaceut ... | Mueller Brian | Option Exercise | A | 1.65 | 84,705 | 139,763 | 84,705 | ||
Jun 23 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | M | 21.51 | 2,671 | 57,453 | 0 | |
Jun 23 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 100.00 | 2,671 | 267,100 | 12,885 | 15.6 K to 12.9 K (-17.17 %) |
Jun 23 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Buy | M | 21.51 | 2,671 | 57,453 | 15,556 | 12.9 K to 15.6 K (+20.73 %) |
Jun 06 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 90.72 | 376 | 34,111 | 12,885 | 13.3 K to 12.9 K (-2.84 %) |
May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 91.50 | 207 | 18,941 | 13,261 | 13.5 K to 13.3 K (-1.54 %) |
May 10 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | M | 21.51 | 2,600 | 55,926 | 2,671 | |
May 10 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 93.17 | 2,600 | 242,242 | 13,468 | 16.1 K to 13.5 K (-16.18 %) |
May 10 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Buy | M | 21.51 | 2,600 | 55,926 | 16,068 | 13.5 K to 16.1 K (+19.31 %) |
May 10 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 91.17 | 4,882 | 445,092 | 13,468 | 18.4 K to 13.5 K (-26.60 %) |
May 10 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 70.30 | 270 | 18,982 | 18,350 | 18.1 K to 18.4 K (+1.49 %) |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | A | 87.42 | 7,740 | 676,631 | 7,740 | |
Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 0.00 | 4,790 | 0 | 18,080 | 13.3 K to 18.1 K (+36.04 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 90.96 | 376 | 34,201 | 13,290 | 13.7 K to 13.3 K (-2.75 %) |
Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 92.50 | 336 | 31,080 | 13,666 | 14 K to 13.7 K (-2.40 %) |
Aug 03 2016 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Sell | S | 100.00 | 287 | 28,700 | 14,260 | 14.5 K to 14.3 K (-1.97 %) |
Jun 07 2016 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Payment of Exercise | F | 90.00 | 376 | 33,840 | 14,547 | 14.9 K to 14.5 K (-2.52 %) |
May 17 2016 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Payment of Exercise | F | 82.71 | 207 | 17,121 | 14,923 | 15.1 K to 14.9 K (-1.37 %) |
May 10 2016 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Payment of Exercise | F | 80.80 | 444 | 35,875 | 15,130 | 15.6 K to 15.1 K (-2.85 %) |
May 10 2016 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Grant | A | 51.26 | 327 | 16,763 | 15,574 | 15.2 K to 15.6 K (+2.14 %) |
Apr 29 2016 | ANTH | Anthera Pharmaceut ... | Mueller Brian | Option Exercise | A | 3.80 | 41,379 | 157,240 | 41,379 | ||
Mar 17 2016 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Option Exercise | A | 83.43 | 7,000 | 584,010 | 7,000 | |
Mar 17 2016 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Payment of Exercise | F | 80.34 | 376 | 30,208 | 15,247 | 15.6 K to 15.2 K (-2.41 %) |
Mar 17 2016 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Grant | A | 0.00 | 3,570 | 0 | 15,623 | 12.1 K to 15.6 K (+29.62 %) |
Dec 24 2015 | ANTH | Anthera Pharmaceut ... | Mueller Brian | Option Exercise | M | 2.89 | 10,000 | 28,900 | 2,500 | ||
Dec 24 2015 | ANTH | Anthera Pharmaceut ... | Mueller Brian | Buy | M | 2.89 | 10,000 | 28,900 | 10,000 | 0 to 10 K | |
Jun 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Payment of Exercise | F | 120.46 | 522 | 62,880 | 11,926 | 12.4 K to 11.9 K (-4.19 %) |
Jun 03 2015 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Payment of Exercise | F | 125.57 | 308 | 38,676 | 12,448 | 12.8 K to 12.4 K (-2.41 %) |
May 22 2015 | ANTH | Anthera Pharmaceut ... | Mueller Brian | Option Exercise | A | 4.75 | 28,846 | 137,019 | 28,846 | ||
May 19 2015 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Payment of Exercise | F | 122.78 | 207 | 25,415 | 12,756 | 13 K to 12.8 K (-1.60 %) |
May 12 2015 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Payment of Exercise | F | 121.66 | 444 | 54,017 | 12,963 | 13.4 K to 13 K (-3.31 %) |
May 12 2015 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Grant | A | 51.26 | 607 | 31,117 | 13,407 | 12.8 K to 13.4 K (+4.74 %) |
Mar 17 2015 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Option Exercise | A | 124.37 | 9,000 | 1,119,330 | 9,000 | |
Mar 17 2015 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Grant | A | 0.00 | 4,000 | 0 | 12,800 | 8.8 K to 12.8 K (+45.45 %) |
Mar 05 2015 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Option Exercise | M | 28.23 | 7,000 | 197,610 | 7,491 | |
Mar 05 2015 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Sell | S | 109.46 | 7,000 | 766,210 | 8,800 | 15.8 K to 8.8 K (-44.30 %) |
Mar 05 2015 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Buy | M | 28.23 | 7,000 | 197,610 | 15,800 | 8.8 K to 15.8 K (+79.55 %) |
Mar 05 2015 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Option Exercise | A | 63.10 | 10,000 | 631,000 | 10,000 | |
Mar 05 2015 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | VP, Corporate Contr ... | Grant | A | 0.00 | 4,000 | 0 | 8,800 | 4.8 K to 8.8 K (+83.33 %) |
Page: 1